Clinical trials: Ovarian
Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment…
- Conditions
- Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms, Ovarian Endometrioid Carcinoma, High-grade Serous Ovarian Carcinoma (HGSOC)
- Trial name
- OVPrecision (NCT06466382)
- Testing
- Treatment recommendation by molecular tumorboard (mTB) based on tumor profiling, Carboplatin / Paclitaxel Chemotherapy
- Where
- 10 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Swiss GO Trial Group
Breast Cancer Female, Ovarian Cancer
Diet, Hepcidin, and Chemotherapy RDI
This prospective, observational cohort study will evaluate the extent of associations between self-reported pro- or anti- inflammatory dietary intake patterns for one month before induction chemotherapy for gynecological cancer…
- Conditions
- Breast Cancer Female, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT06483997
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- George Washington University
Ovarian Neoplasms
A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass
Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine…
- Trial name
- NCT06566716
- Testing
- CleoDX ovarian cancer test
- Where
- 19 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Cleo Diagnostics Ltd
Ovarian Neoplasms, Breast Neoplasms
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP).
- Conditions
- Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
- Trial name
- FiREBOLT (NCT07213791)
- Testing
- LY4337713
- Where
- 30 sites in United States, China and 3 more
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Malignant Germ Cell Tumor, Lung Adenocarcinoma
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian…
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT07705035
- Testing
- DBC-664
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Duboce Biopharmaceuticals, Inc.
Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer
Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer
Epithelial ovarian cancer, which includes fallopian tube and primary peritoneal cancer, is the deadliest gynecologic malignant neoplasm.
- Conditions
- Platinum-Resistant FRα-Positive Ovarian Cancer, Platinum-Resistant FRα-Positive Fallopian Tube Cancer, Platinum-Resistant FRα-Positive Peritoneal Cancer
- Trial name
- MIRELA (NCT07896421)
- Where
- Austria
- Volunteers
- 500 people
- Sponsor
- AbbVie
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC
No Evidence of Disease, BRCA1 Syndrome
Culturally-Informed Counseling in Latinas at High Risk for Hereditary Breast or Ovarian Cancer
This pilot clinical trial studies a culturally-informed counseling intervention in Latinas at high risk for hereditary breast or ovarian cancer.
- Conditions
- No Evidence of Disease, BRCA1 Syndrome, BRCA2 Syndrome, Hereditary Female Breast Carcinoma
- Trial name
- NCT01230346
- Testing
- questionnaire administration, survey administration, counseling intervention
- Where
- 3 sites in United States
- Volunteers
- 493 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
This phase I trial studies the side effects and how well surgery and heated chemotherapy with or without non-heated chemotherapy after surgery works in treating patients with ovarian, fallopian tube, uterine, or peritoneal…
- Conditions
- FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT01970722
- Testing
- Carboplatin, Cisplatin, Gemcitabine Hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- City of Hope Medical Center
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back…
- Conditions
- Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
- Trial name
- NCT02839707
- Testing
- Atezolizumab, Bevacizumab, Computed Tomography
- Where
- 919 sites in United States, Puerto Rico
- Volunteers
- 444 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm
Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial Cancer
This phase II trial studies how well tazemetostat works in treating patients with ovarian or endometrial cancer that has come back (recurrent).
- Conditions
- Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma
- Trial name
- NCT03348631
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Tazemetostat
- Where
- 581 sites in United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor
International PPB/DICER1 Registry
PPB has strong genetic implications, with a unique set of conditions in an individual or their family, occurring mostly in childhood and adolescence.
- Conditions
- Pleuropulmonary Blastoma, Sertoli-Leydig Cell Tumor, DICER1 Syndrome, Cystic Nephroma
- Trial name
- NCT03382158
- Where
- United States
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- Children's Hospitals and Clinics of Minnesota
Solid Tumor, Adult, Colorectal Cancer
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Cancer
- Trial name
- BASECAMP-1 (NCT04981119)
- Testing
- Apheresis, Next Generation Sequencing (NGS), Long Range NGS HLA typing
- Where
- 16 sites in United States
- Volunteers
- 500 people
- Sponsor
- A2 Biotherapeutics Inc.
Acute Ovarian Failure, Infertility
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
Background: Medical advances have improved survival rates for many cancers and other illnesses. This means that more people are coping with the long-term effects of these treatments. Some treatments can cause female infertility.
- Conditions
- Acute Ovarian Failure, Infertility, Early Menopause And Infertility In Females After Treatment For Childhood Cancer
- Trial name
- NCT05440617
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Solid Cancer
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
- Trial name
- NCT06161025
- Testing
- R-DXd, Paclitaxel, Topotecan
- Where
- 167 sites in United States, Australia and 17 more
- Volunteers
- 860 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumor, Melanoma
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced unresectable or metastatic solid tumors.
- Conditions
- Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
- Trial name
- NCT06172478
- Testing
- HER3-DXd
- Where
- 96 sites in United States, Australia and 14 more
- Volunteers
- 740 people
- Sponsor
- Daiichi Sankyo
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Solid Tumor, Ovarian Cancer
A Phase I Study of XS-02 Capsules in Patients With Advanced Solid Tumors
A study to evaluate the safety, tolerability, pk, and efficacy of XS-02 capsules in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Ovarian Cancer, Breast Cancer, Endometrial Cancer
- Trial name
- NCT06531486
- Testing
- XS-02 capsules
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Ovarian Cancer Recurrent, Ovarian Cancer
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
The goal of this clinical trial is to learn if OPB-101 is safe in platinum resistant ovarian cancer participants and also to find the optimal dose of OPB-101.
- Conditions
- Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer
- Trial name
- NCT07030907
- Testing
- OPB-101
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Outpace Bio, Inc.